Change Language
wds-media
  • Home
  • Health
VA Medical Center to use ViewRay’s MRIdian system to treat cancer

VA Medical Center to use ViewRay’s MRIdian system to treat cancer

The VA Oklahoma City Healthcare System has chosen ViewRay’s MRIdian MRI-guided radiation therapy system to expand its radiation therapy services at the Oklahoma City VA Medical Center.

This selection makes it the first cancer centre in Oklahoma and the fourth VA medical centre to offer advanced MRI-guided radiation therapy for cancer treatment.

According to ViewRay, the MRIdian system will enable the Oklahoma City VA Medical Center to provide precise and personalised treatment for various cancers, including pancreatic, prostate, lung, liver, breast, and oligometastatic disease.

ViewRay executive vice president and CCO Paul Ziegler said: “ViewRay is proud to be working with VA Oklahoma City Healthcare System, a talented group of clinicians committed to bringing patients the benefit of precise and personalised radiation therapy.

“We are excited to see another VA healthcare system join the growing MRIdian community.

“Expanding the availability of MRIdian’s short-course non-invasive therapy with fewer side effects and better quality of life is an important advancement for our Veterans.”

Other VA medical centres that will also offer MRIdian MRI-guided radiation therapy include those in Cleveland, Ann Arbor, and Houston.

The MRIdian system provides oncologists with diagnostic MR images for anatomical visualisation and allows them to adapt radiation therapy plans to target cancer with the patient on the table.

This technology helps define treatment margins, minimise radiation exposure to healthy tissue, and deliver ablative radiation doses in a limited number of sessions.

Over 31,000 patients have been treated with MRIdian globally, and it is currently installed in 62 hospitals worldwide.

The post VA Medical Center to use ViewRay’s MRIdian system to treat cancer appeared first on Hospital Management.

USD/JPY –  17.10.2024

USD/JPY – 17.10.2024

Read More